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Snake envenoming is a serious and neglected public health crisis that is responsible 
for as many as 125,000 deaths per year, which is one of the reasons the World Health 
Organization has recently reinstated snakebite envenoming to its list of category A 
neglected tropical diseases. Here, we investigated the ability of human mast cell prote-
ases to detoxify six venoms from a spectrum of phylogenetically distinct snakes. To this 
end, we developed a zebrafish model to assess effects on the toxicity of the venoms 
and characterized the degradation of venom proteins by mass spectrometry. All snake 
venoms tested were detoxified by degradation of various venom proteins by the mast 
cell protease tryptase β, and not by other proteases. Our data show that recombinant 
human tryptase β degrades and detoxifies a phylogenetically wide range of venoms, 
indicating that recombinant human tryptase could possibly be developed as a universal 
antidote to venomous snakebites.
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inTrODUcTiOn
The development of affordable and effective non-species-specific antivenom could dramatically 
reduce the global burden of snakebite (1). Yearly, up to 2,500,000 cases result in as many as 125,000 
deaths and 400,000 amputations worldwide, with by far the highest rates occurring in poor and 
rural areas of South and Southeast Asia, sub-Saharan Africa, and Oceania (1–4). In addition to the 
morbidity and mortality, the economic burden of snakebites is considerable (5), especially as most 
victims of snakebite live in the world’s poorest communities, with agricultural workers, children, 
and rural dwellers most at risk (6).
Current treatments for snakebite are problematic for several reasons. Apart from political and 
economic factors that have led to a dramatic loss of antivenom manufacturers and insufficient 
product regulation in Africa, Asia, and Oceania (7), there are a number of technical problems 
inherent in this treatment. For example, antisera are species-specific, proper usage requires both 
accurate species identification and availability of the corresponding antivenom, and they must be 
administered intravenously at often difficult to reach clinics. Even then, antibody sera come with 
an inherent risk of adverse immune side effects, including anaphylactic shock (8–10). For example, 
more than 50% of patients receiving a horse-derived antivenom developed early adverse reaction 
FigUre 1 | Whole venom from six different snakes induces degranulation of human mast cells. LAD2 MCs (a) or primary human skin mast cell (hsMCs) isolated 
from three healthy donors (B) were stimulated with venom from the six listed snake species. (B) Venom doses were as follows: common lancehead, saw-scaled 
viper, southern copperhead, red spitting cobra, Russell’s viper, and western diamondback rattlesnake. Negative controls (vehicle) were PBS only. Positive controls 
(not shown) were Ca ionomycin (1 µM) and caused an average of 55% degranulation in LAD2 (a), and 62, 36, and 8% degranulation in hsMCs from each donor (B). 
Data are pooled from four independent experiments and measurements were performed in triplicate. Student’s t-test compares venom to vehicle stimulation. 
*p < 0.05; **p < 0.01; ***p < 0.001.
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to the antivenom with 30% experiencing severe anaphylaxis (11). 
Thus, a non-species-specific treatment that could be immediately 
and locally administered without the risk of adverse immune 
reactions would be a significant improvement.
We and others have recently shown that in mice, mast cells 
(MCs) can limit the toxicity of animal venoms by releasing pro-
teases that degrade and thereby detoxify venom components. 
The proteases carboxypeptidase A (CPA) and chymase mouse 
MC protease-4 were found to be responsible for the protective 
effects of MC against various animal venoms (12–14). To date, 
the role of human MC-derived proteases in responses to snake 
venoms has not been reported. If protective, these proteases 
could be developed as a novel local treatment for envenoming by 
a broad range of snake species.
MaTerials anD MeThODs
Mast cells
The MC line LAD2 was kindly provided from Dr. Arnold S. 
Kirshenbaum (National Institute of Allergy and Infectious 
FigUre 2 | Lysate from purified human skin mast cells (hsMCs) protects 
zebrafish from toxicity of cobra venom. Zebrafish embryos aged 48 h post 
fertilization suspended in 100 µl of fish water received 625 ng red spitting 
cobra whole venom pre-treated with lysate of purified hsMCs (MC lysate) or 
PBS (vehicle). Lysate doses were 12-, 6-, or 3- thousand cells per fish. 
Survival was monitored at regular intervals for 6 h, with complete cessation of 
heartbeat as the predefined endpoint. Vehicle, lysate alone, or enzyme alone 
had no effect (data not shown). Data are pooled from three independent 
experiments, n = 12 fish per group. Kaplan–Meyer survival analysis, Log-rank 
(Mantel-Cox) test compares treatments to vehicle and to each other. 
**p < 0.01; ***p < 0.001.
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Diseases, Bethesda, MD, USA) and cultured as described 
(15).
Human skin mast cells (hsMCs) were isolated according to 
a published protocol (16) with modifications as reviewed and 
approved by the Charité—Universitätsmedizin Berlin Institu-
tional Review Board. Human abdominal skin from healthy adults 
undergoing abdominoplasty was cut into strips and treated 
with Dispase Type I (Roche Diagnostics) at 2.4  U/ml and 4°C 
overnight. The dermis was cut into small pieces and digested with 
collagenase (Worthington) at 10  mg/g of tissue, hyaluronidase 
(Sigma-Aldrich) at 5–7.5  mg/g, and 10  µg/ml DNAse (Roche 
Diagnostics) suspended in 10  ml of dispersing medium per g 
(PBS, 1% penicillin/streptomycin, 5% FCS, 1.5 µg/ml Amphote-
ricin B, 5 mM MgSO4) for 1 h at 37°C. The isolated cells were 
separated from the remaining tissue by three steps of filtration 
(pore sizes 100, 40, and 20 µm) and the digestion was repeated 
one to two times. MCs were further purified from the suspension 
by positive selection using anti-CD117 magnetic microbeads 
(Miltenyi) and a magnetic cell sorter. MC purity in these sepa-
rations typically exceeded 95%, as assessed by Kimura staining. 
Informed consent of the patients has been obtained.
β-hexosaminidase release assay
We stimulated a total of 1.5 × 105 LAD2 MC or 0.6–1.5 × 105 puri-
fied hsMCs in Tyrode’s buffer [10 mM HEPES buffer (pH 7.4), 
130 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.4 mM CaCl2, 5.6 mM 
glucose, and 0.1% BSA] with the indicated concentrations of 
snake venom or 1 µM calcium ionomycin (Sigma-Aldrich) for 
30 min at 37°C and performed β-hexosaminidase release assay as 
previously described by us and others (14, 17–19). In brief, after 
stimulation with venoms, cells were separated by centrifugation 
and β-hexosaminidase levels were measured in both supernatants 
and in cell pellets. MC degranulation was then assessed as percent-
age release of total β-hexosaminidase.
Venoms and Proteases
Venoms from Agkistrodon contortrix contortrix (southern cop-
perhead), Crotalus atrox (western diamondback rattlesnake), and 
Echis carinatus (saw-scaled viper) were purchased from Sigma-
Aldrich; venoms from Bothrops atrox (common lancehead), 
Daboia russelii (Russell’s viper), and Naja pallida (red spitting 
cobra) from Latoxan, France. Purified human lung tryptase, 
purified human pancreas CPA, and purified human skin chymase 
were purchased from Elastin Products Company, MO, USA.
Venom concentrations used for MC stimulation and zebrafish 
survival assays were based on published LD50s, adjusted for the 
respective experimental setting. Final concentrations for MC 
activation were 125 µg/ml common lancehead; 25 µg/ml saw-scaled 
viper; 30 µg/ml southern copperhead; 7.5 µg/ml red spitting cobra; 
20 µg/ml Russell’s viper; and 200 µg/ml western diamondback 
rattlesnake. Final concentrations for zebrafish assays were 
1,000  µg/ml common lancehead; 200  µg/ml saw-scaled viper; 
400  µg/ml southern copperhead; 6.25  µg/ml red spit ting cobra; 
300 µg/ml Russell’s viper; and 1,000 µg/ml western diamondback 
rattlesnake.
recombinant Tryptase β
Recombinant human tryptase β was expressed in Pichia pastoris 
and isolated by a modification of published methods (20, 21). 
The purity of the recombinant protease was ≥95% as deter-
mined by SDS-PAGE and N-terminal amino acid sequencing. 
The specific activity, quantified by both burst titration with 4- 
methylumbelliferyl p-guanidinobenzoate and titration with 
synthetic inhibitors (22), was ≥90% of the theoretical value. Inac-
tivated tryptase was prepared by reaction with 4-(2-Aminoethyl)-
benzenesulfonyl fluoride hydrochloride (Roche Diagnostics) and 
subsequent removal of residual reagents. Recombinant human 
tryptase was stabilized routinely with unfractionated heparin 
from bovine intestinal mucosa (Sigma-Aldrich).
Zebrafish survival assays
Wild-type Zoltan zebrafish were provided by Salim Seyfried, 
Max-Delbrück-Center for Molecular Medicine, Berlin. Zebrafish 
maintenance and embryo collection were carried out according 
to the standard practice. At 48 h post fertilization (hpf), embryos 
were transported to our lab for same-day use shortly after hatch-
ing. Fish were kept at 27°C. Assays were performed at 20–25°C.
For the survival experiments, zebrafish embryos were indi-
vidually suspended in 50 µl of egg water in a 96-well microtiter 
plate and 50 µl venom/treatment solutions were added for final 
volume of 100 µl. For assays of hsMC lysate treatment, freshly 
purified hsMCs were resuspended in PBS, lysed by ultrasonica-
tion and stored at −80°C. Lysate from four different donors was 
pooled and diluted in PBS, and incubated at various concentra-
tions with venom for 60 min at 37°C, which was then transferred 
to microwells containing single zebrafish for toxicity testing. 
Likewise, purified human tryptase, chymase, CPA, or recom-
binant tryptase β were first combined in PBS and incubated at 
FigUre 3 | Purified human tryptase, but not chymase or carboxypeptidase A (CPA), detoxifies snake venoms. Venoms were incubated with 10 µg/ml human 
tryptase, chymase, or CPA. Treated and untreated venom were then administered to 48 h post fertilization zebrafish in 100 µl of water. Empty circles represent 
zebrafish receiving venom alone, and solid shapes represent fish receiving enzyme-treated venom. Vehicle or enzyme alone had no effect (data not shown). Data  
are pooled from three (tryptase) or two (chymase and CPA) independent experiments for n = 15 or 10 fish per group. Kaplan–Meyer survival analysis, Log-rank 
(Mantel-Cox) test compares treatments to vehicle. **p < 0.01; ***p < 0.001.
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37°C for 60 min at indicated concentrations before exposure to 
embryos.
To test hsMC lysate or purified human tryptase treatments 
given at short time intervals after initial venom exposure, venom 
alone (also incubated at 37°C for 60 min prior to use) was added 
to microwells as above. Subsequently, 10 µl of a 10× concentrated 
solution of lysate or tryptase treatment was added to the wells at 
the indicated time points.
Controls were prepared with identical concentrations of 
venom, enzyme, lysate, or PBS alone. Active recombinant tryptase 
FigUre 4 | MALDI-TOF-MS analysis of venoms treated with purified human tryptase shows degradation of venom proteins. Samples were prepared at 
concentrations of 10 µg/µl venom and a ratio of 1000:1 venom to tryptase by mass (southern copperhead and common lancehead) or 0.1 µg/µl and a ratio of 10:1 
venom to tryptase by mass (western diamondback rattlesnake, Russell’s viper, saw-scaled viper, and red spitting cobra). They were then incubated at 37°C for 
30 min, and stored at −20°C. Control was prepared with venom and PBS alone. 17 µl of the venom sample (in PBS) was purified by reversed phase 
chromatography using C18 Zip TipsTM (Millipore). Mass spectra were acquired in positive ion reflectron mode within the m/z ratio range of m/z 3,500 to m/z 18,000. 
Panel (a) shows a representative MALDI-TOF-MS spectrum of red spitting cobra venom before and after incubation with purified human tryptase. Five signals 
(dashed arrows) over the acquired mass range were selected and their signal intensities normalized to the intensity of the doubly charged myoglobin signal (m/z 
8,477). The relative signal intensity reduction of several peaks indicates protein degradation by tryptase. Spectra for additional venoms are provided in Figure 5. 
Comparisons of relative signal intensities for all six venoms are summarized in (B). Arrows indicate a reduced (↓) or increased (↑) relative signal intensity difference 
(Intens. dif.) of prominent peaks, or no difference (no dif.), with lower peaks indicating degradation of the polypeptide of the corresponding m/z ratio.
5
Anderson et al. Tryptase as Universal Antivenom
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1532
β contained a ratio of 12:1 heparin to tryptase for tetramer 
stabilization. Zebrafish were monitored at regular intervals at 
40× magnification using a standard inverted microscope. Death 
was defined as cessation of the heartbeat, which is clearly vis-
ible through the transparent skin at this stage of development. 
Zebrafish that survived at least 6  h were generally observed to 
remain alive at least 24 h.
Mass spectrometry (Ms) analysis
Samples were prepared at a ratio of 103:1 venom to tryptase by 
mass (southern copperhead and common lancehead) or 10:1 
venom to tryptase by mass (western diamondback rattlesnake, 
Russell’s viper, saw-scaled viper, red spitting cobra) in PBS, incu-
bated at 37°C for 30  min, and stored at −20°C. Controls were 
prepared with venom and PBS alone.
A6
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MalDi-TOF-Ms analysis
MALDI-TOF-MS analyses were performed on an AutoflexTM 
Speed mass spectrometer using an AnchorChip (800/384) 
MALDI target plate (Bruker Daltonics, Bremen, Germany). Mass 
spectra were acquired in positive ion reflectron mode within the 
mass range of m/z 3,500 to m/z 18,000, collecting 10,000 shots 
(smartbeam™-II laser) with constant laser intensity, averaged 
over the entire spot. External calibration of the TOF analyzer was 
performed prior the first analysis of a batch using protein calibra-
tion standard I (Bruker Daltonics, Bremen, Germany).
Prior to MALDI-TOF-MS analyses, 17 µl of the venom sample 
(in PBS) were purified by reversed phase chromatography using 
C18 Zip TipsTM (Millipore). The tips were flushed with 70% 
acetonitril (ACN) containing 0.1% trifluoroacetic acid (TFA) and 
equilibrated with 5% ACN/0.1% TFA prior sample purification. 
The sample was applied to the tip by repeated pipetting (20 times) 
according to the manufacturer’s instructions. Bound peptides/
proteins were desalted by washing the tip five times with 20 µl 
of 5% ACN/0.1% TFA before the bound components were eluted 
with 11 µl of 70% ACN/0.1% TFA.
Equal volumes (2 µl each) of the individually purified sam-
ples were mixed with 2 µl of horse heart myoglobin (1 µg/µl) 
as an internal reference. One microliter of the mix followed by 
another microliter of 2,5-dihydroxybenzoic acid matrix (DHB, 
10 mg/ml in 30% ACN/0.1% TFA, Sigma-Aldrich) were spotted 
onto the MALDI target plate and dried under ambient condi-
tions at RT.
The acquired mass spectra were manually analyzed using 
Data Analysis 4.0 (Bruker Daltonics). Five intense signals distrib-
uted over the acquired mass range were selected and their signal 
intensities normalized to the intensity of the doubly charged 
signal of myoglobin (m/z 8,476) to semi-quantitatively evaluate 
the change in signal intensities by tryptase treatment. Further 
detail is provided in the Protein Report in Supplementary 
Material.
reversed Phase lc-esi-Ms/Ms
Samples were analyzed by RP-LC-ESI-MS/MS on an amaZon 
ETD ion trap (Bruker Daltonics, Bremen, Germany) coupled to 
an Ultimate 3000 UHPLC system (Dionex, Part of Thermo Fisher) 
FigUre 5 | Continued
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as described previously, with minor modifications (23). Peptide 
MS/MS spectra were searched against the SwissProt database 
using ProteinScape 3.1 (Bruker Daltonics, Bremen, Germany) and 
MASCOT 2.3 (MatrixScience, London, UK) using the following 
search parameters in the UniProt database (Release 2011_08 and 
reanalyzed with 2013_08): deamidation (Asn/Gln) and oxidation 
(Met) were set as variable modifications and chordata was chosen 
as taxonomy. Up to nine missed cleavages were allowed selecting 
trypsin as acting enzyme. The high number of missed cleavages 
was used since tryptase cleaves after the same amino acids as 
trypsin but with higher selectivity. Peptide tolerance (both MS 
and MS/MS) was set at ±0.2 Da.
resUlTs
snake Venom induces human Mast cell 
Degranulation
To test whether clinically relevant snake venoms can activate 
human MCs we first stimulated LAD2 cells with venom from 
six taxonomically and geographically diverse venomous snakes, 
which are all listed by the World Health Organization as snakes 
with a high medical importance in their respective region 
(1, 24–26). All venoms induced dose-dependent MC degranula-
tion as assessed by β-hexosaminidase release (Figure 1A). Since 
LAD2 cells differ considerably from primary hsMCs [for example, 
they contain comparatively low levels of proteases (27)] we also 
tested freshly isolated and purified hsMCs. Skin MCs from three 
individual healthy donors degranulated in the presence of all 
tested venoms (Figure 1B).
human Mast cells Protect Zebrafish 
embryos From lethal Doses of  
snake Venom
Next, we tested whether hsMC can neutralize the toxic effects 
of snake venom. Traditionally, venom toxicity is quantified as 
the amount required to kill 50% of a test population of mice, i.e. 
the lethal dose, 50% (LD50) (28). To avoid using an unethically 
high number of mice, we developed an alternative model for the 
assessment of the biological activity of venoms using zebrafish 
embryos at 48 hpf. With this model, we first measured rates of 
FigUre 5 | Continued
C8
Anderson et al. Tryptase as Universal Antivenom
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1532
survival of zebrafish embryos exposed to red spitting cobra venom 
that had or had not been treated with lysates of purified hsMCs. 
Lethality of the cobra venom was markedly reduced when the 
venom was treated with MC lysates from as little as 3,000 MCs 
per fish (Figure 2). Lysates from larger numbers of MCs resulted 
in increased survival rates of the zebrafish embryos, with almost 
complete protection after incubation with lysate from 12,000 MC 
(Figure 2).
Purified human Tryptase Detoxifies  
snake Venom
Based on previous reports by us and others showing that mouse 
MC proteases are able to detoxify snake venom or snake venom 
components (13, 29), we hypothesized that the observed detoxi-
fication of red spitting cobra venom by MC lysates is mediated 
by MC-derived proteases. To verify this, and to assess whether 
other snake venoms can also be detoxified by MC proteases, we 
tested three prominent human MC proteases—tryptase, chymase, 
and CPA—for protective effects in the zebrafish model. Purified 
human skin chymase and purified human pancreatic CPA had 
no protective effect against any of the venoms (Figure 3), while 
both enzymes were confirmed to be active by degradation of 
specific chromogenic substrates (data not shown). By contrast, 
purified human lung tryptase completely protected zebrafish 
embryos from the lethal effects of common lancehead, red 
spitting cobra, southern copperhead, and western diamond-
back rattlesnake venom and significantly improved survival of 
embryos exposed to Russell’s viper and saw-scaled viper venoms 
(Figure 3).
Mast cell Tryptase Degrades snake 
Venom Toxins
To investigate how tryptase provides protection from the toxic 
effects of snake venoms, we used MS to compare tryptase-treated 
and untreated venom from cobra (Figure  4A) and five other 
snakes (Figure 5). MALDI-TOF-MS analyses showed reduction 
in the intensities of 23 out of 30 signals for venom proteins after 
treatment with purified human tryptase (Figure 4B). The loss of 
numerous signature venom components in all six snake species 
tested suggests degradation by tryptase.
To verify that proteins with decreased signal intensity had 
in fact been degraded, we used reversed phase LC-ESI-MS/MS 
analysis to test for small peptide fragments in tryptase-treated and 
untreated venoms. Peptides derived from l-amino-acid oxidase 
FigUre 5 | Continued
DFigUre 5 | Continued
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were identified in five venoms after tryptase treatment, but not in 
the control samples, indicating degradation by tryptase (Table 1). 
The high peptide sequence homology (30) allowed for successful 
identification of this protein even in species where only closely 
related protein sequences are available (southern copperhead and 
common lancehead).
human Mast cell Mediators reduce the 
Mortality of Zebrafish exposed to lethal 
Doses of cobra Venom
To test whether human tryptase can protect against the lethal 
effects of snake venom when administered subsequent to initial 
exposure to venom, we first exposed zebrafish embryos to lethal 
doses of cobra venom, and then administered pooled lysate 
from purified hsMCs 1, 5, or 10  min later. Survival rates were 
significantly higher in all lysate-treated groups compared to 
those receiving vehicle only, with strong or complete protection 
of the zebrafish embryos (Figure 6A). We next performed similar 
experiments applying purified human tryptase 1, 5, 10, 20, 30, 
and 40 min following cobra venom exposure, with significantly 
higher survival rates for embryos that received tryptase treatment 
after up to 30 min when compared with embryos receiving no 
treatment (Figure 6B).
recombinant human Tryptase β Detoxifies 
snake Venom
Purified human tryptase is only 95% pure and contains buffer 
components, heparin, and sodium azide as biologically active 
compounds. Therefore, and because recombinant human tryptase 
β is the likely option for the clinical treatment of snakebite, we 
verified the role of tryptase and the efficacy of a recombinant pro-
tease. Recombinant human tryptase β was incubated with venom 
from five different snakes and administered to 48 hpf zebrafish 
as before. Tryptase-treated lancehead, cobra, copperhead, and 
rattlesnake venom produced 100% survival and tryptase-treated 
viper venom was significantly less deadly than venom alone 
(Figure  7). To rule out non-enzymatic mechanisms of venom 
detoxification, for example, by binding of venom components to 
the recombinant tryptase β, we performed experiments compa-
ring active and inactivated recombinant tryptase. Inactive recom-
binant human tryptase β showed no protective effect, verifying 
the need for an enzymatically active protease (Figure 7).
EFigUre 5 | MALDI-TOF-MS analyses of whole venoms treated with purified human tryptase shows degradation of venom proteins. Venoms from five snake species 
[(a) common lancehead, (B) saw-scaled viper, (c) southern copperhead, (D) russel’s viper, (e), western diamondback rattlesnake] were treated with tryptase or 
vehicle control. Spectra were acquired within the mass range of m/z 3,500 to m/z 18,000. Samples contain equal amounts (0.5 µg) myoglobin as an internal 
reference (m/z 16,952 [M + H]+, m/z 8,476 [M + 2H]2+, m/z 5,651 [M + 3H]3+). Venom-derived signals (dashed arrows) distributed over the whole mass range were 
selected and normalized to the intensity of the doubly charged myoglobin signal (Figure 4B). The reduction in relative signal intensities of several peaks in 
tryptase-treated versus untreated venom indicates tryptase-mediated protein degradation.
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DiscUssiOn
Currently, the only validated treatment for severe snakebite 
envenomation is passive immunization by i.v. infusion of 
animal-derived antisera, a treatment which has proven to be 
effective, but which is often not available for those needing it the 
most (31). The reasons for this include the cost of production, 
the need for accurate species identification, and the availability 
of the respective antisera. Novel treatment options that avoid these 
problems could be a great help in the management of snakebite 
envenomation. Here, we show that human tryptase β degrades 
and detoxifies venoms from a broad spectrum of phylogenetically 
distinct snakes, making recombinant tryptase a potential treat-
ment for snakebite envenoming.
Snake fangs usually deliver venom to the dermis or in subcuta-
neous fat tissue, where MCs are abundant (32). Since mouse MCs 
are capable of reducing the toxicity of certain animal venoms 
and venom components (12–14), we hypothesized that human 
MCs can also limit venom toxicity. We show that primary hsMCs 
are activated to release preformed mediators upon exposure to 
venom from six different snake species, suggesting that human 
MC products may provide some evolutionarily derived defense 
against animal venoms, and pointing to a new pharmaceutical 
avenue for broadly treating snake envenoming.
To measure detoxification of snake venom by human MCs, 
we sought a biological toxicity assay that would allow for efficient 
screening of multiple treatments and venoms at various doses. 
Using zebrafish embryos 48 hpf, we verified that lysates from 
freshly isolated hsMC are sufficient to detoxify cobra venom. We 
proceeded to assess detoxifying effects of three purified human 
mast cell proteases on venom from six different snake species. We 
found that human tryptase is responsible for this detoxification. 
This is in contrast to findings in mouse models where CPA (12) and 
chymase (14) were found to be protective. The extent of protection 
TaBle 1 | Venom protein identification using LC-ESI-MS/MS reveals peptide fragments of known venom toxins in samples treated with purified human tryptase.
Type of 
fragmentation
UniProt  
entry name
Protein name Protein  
mass  
(kDa)
Observed 
peptide  
(m/z)
charge 
state
Mass 
difference  
(ppm)
Peptide sequence Protein 
score
Southern 
copperhead + tryptase
CID OXLA_BOTJR l-amino-acid oxidase (fragment) OS = Bothrops jararacussu 
PE = 1 SV = 1
56.30 441.34 3 155.90 RIKFEPPLPPK 70.21
432.00 3 148.58 IKFEPPLPPKK
Common 
lancehead + tryptase
CID OXLA_BOTJR l-amino-acid oxidase (fragment) OS = Bothrops jararacussu  
PE = 1 SV = 1
56.30 441.35 3 178.56 RIKFEPPLPPK 146.69
463.60 3 90.68 KFWEDDGIHGGK
420.93 3 167.17 FWEDDGIHGGK
438.78 2 126.03 STTDLPSR
Western diamondback 
rattlesnake + tryptase
CID OXLA_CROAD l-amino-acid oxidase OS = Crotalus adamanteus  
PE = 1 SV = 1
58.60 438.68 2 −11.11 VIEIQQNDR 65.46
557.79 2 −101.90 STTDLPSR
CID VM1AC_CROAT Snake venom metalloproteinase atrolysin-C OS = Crotalus atrox 
PE = 1 SV = 1
46.70 548.24 2 −64.01 YNSDLNTIR 90.91
430.67 2 −132.91 ETDLLNR
CID VM1A2_CROAD Snake venom metalloproteinase adamalysin-2 OS = Crotalus 
adamanteus PE = 1 SV = 2
23.10 554.28 2 −23.97 YNSDLNIIR 62.52
Russell’s viper + tryptase CID OXLA_DABRR l-amino-acid oxidase OS = Daboia russelii PE = 1 SV = 1 56.90 584.78 2 −58.23 VTVTYQTTQK 96.50
520.58 3 −56.45 SGLTAARDVNRASEL
CID IVBI2_DABRR Protease inhibitor 2 OS = Daboia russelii PE = 2 SV = 1 9.70 555.73 2 −25.48 ENTNNFDTR 63.36
677.25 2 −81.37 ENTNNFDTRDK
Saw-scaled 
viper + tryptase
CID OXLA_VIPAA l-amino-acid oxidase OS = Vipera ammodytes ammodytes  
PE = 1 SV = 1
54.70 502.22 2 −108.63 VTVLEASER 48.50
Samples were prepared at a ratio of 103:1 venom to tryptase by mass (southern copperhead and common lancehead) or 10:1 venom to tryptase by mass (western diamondback rattlesnake, Russell’s viper, saw-scaled viper, and red 
spitting cobra) in PBS, incubated at 37°C for 30 min, and subsequently stored at −20°C. Controls were prepared with venom and PBS alone. Samples were analyzed by reversed phase LC-ESI-MS/MS to detect peptide biproducts 
of tryptase digestion. Peptides were detected for all venoms except of red spitting cobra. After incubation with tryptase, l-amino-acid oxidase peptides were detected in five different venoms. In addition, protease inhibitor and 
metalloproteinase peptides were detected in the tryptase-treated venom of Russell’s viper and western diamondback rattlesnake, respectively. Protein reference database was SwissProt.
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FigUre 6 | Skin mast cell lysate and purified human tryptase protects 
zebrafish from cobra venom when administered as a therapy. (a) 48 h post 
fertilization (hpf) zebrafish received 625 ng red spitting cobra whole venom in 
100 µl each. 1, 5, or 10 min after addition of venom, zebrafish were treated 
with lysate from 12 thousand purified human skin mast cells per fish. Data 
are pooled from three independent experiments, with n = 4 zebrafish per 
group, each. (B) 48 hpf zebrafish received 625 ng red spitting cobra whole 
venom in 100 µl each. Between 0 and 40 min after addition of venom, 
zebrafish were treated with 10 µg/ml purified human tryptase. Data are 
pooled from six independent experiments with n = 5 embryos per group, 
each. Lysate, tryptase, or vehicle alone had no effect (data not shown). 
Kaplan–Meyer survival analysis, Log-rank (Mantel-Cox) test compares 
treatments to vehicle. ***p < 0.001.
12
Anderson et al. Tryptase as Universal Antivenom
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1532
by tryptase varied between venoms, likely reflecting the unique 
molecular composition of venom produced by different species.
Tryptase β is the predominant tryptase and serine proteinase 
expressed and stored in human MCs. It is active as a heparin-
stabilized tetramer with trypsin-like activity sterically restricted 
to substrates that penetrate its central cavity to access the 
inward-facing active sites (33). We used MS to determine whe-
ther degradation of venom components was the mechanism 
of detoxification by tryptase. In order to compare protein level 
differences in MALDI-TOF-MS signal intensity in treated versus 
untreated venom, a defined quantity of horse heart myoglobin 
was combined with the treated venoms immediately prior to 
measurement to serve as an internal intensity reference. Degra-
dation of the majority of venom protein peaks by tryptase is 
clearly shown by the lower relative signal intensities of the 
venom components exposed to tryptase (Figure 2). In addition, 
LC-ESI-MS/MS allowed us to identify specific peptide breakdown 
products from several known venom proteins found only in the 
tryptase-treated samples. Notably, the cleavage sites C-terminal 
to arginine and lysine residues in these products match the tryptic 
activity of tryptase β. Among the toxic venom proteins apparently 
degraded by tryptase were an l-amino acid oxidase and a zinc 
metalloproteinase. l-amino acid oxidase is an enzyme found in 
many snake venoms that has been shown to act on platelets and 
induce apoptosis, hemorrhagic effects, and cytotoxicity (30). Zinc 
metalloproteinases, common in crotaline and viperine snake 
venoms, induce capillary hemorrhage and myonecrosis, often 
resulting in permanent tissue loss (34). Inter ference with these 
enzymes would be an important function of therapeutic tryptase.
With only one protease responsible for detoxification of all 
venoms tested, the possibility of developing a simple therapy to 
treat snakebites from a variety of venomous snakes seems feasible. 
As neither MC lysates nor purified human tryptase can be used 
as a therapy in humans, we generated and tested recombinant 
human tryptase β, which could be produced in large quantities 
of pharmaceutical grade product. When treated with this active 
recombinant protease, all tested venoms were significantly reduced 
in toxicity, and four out of the five venoms were rendered 100% 
non-lethal in our toxicity assay.
Our data indicate that recombinant human tryptase β could 
potentially be used as a first aid treatment for snakebite enven-
oming. A major advantage of such an approach is that treatment 
could be initiated immediately after a bite without identification 
of the snake species or access to the species-specific antidote, and 
would not require intravenous administration. Applied locally 
within a short time it could reduce lasting tissue damage and 
minimize the spread of venom while the victim is transported 
to a medical facility for further treatment. A unique feature of 
tryptase makes this treatment approach likely to be very well 
tolerated: in contrast to any other serine protease, tryptase is 
active as a tetramer and the access to the four active sites of the 
tetramer is very limited as they are directed toward its central 
pore (35). This special feature of tryptase prevents it, for example, 
from degrading larger proteins in the skin which would otherwise 
lead to severe damage of the connective tissue.
Several aspects of therapeutic use of tryptase or protease with 
tryptase-like activity require further investigation. (1) Both the 
overall detoxifying ability of tryptase and the therapeutic approach 
have so far only been tested in the zebrafish embryo model. Even 
though our proteomics approach allowed us to verify the deg-
radation of certain venom toxins, different toxins, perhaps with 
increased resistance to tryptase digestion could be responsible 
for toxicity in humans. (2) Although tryptase is locally released 
in the skin by degranulation of MCs without any pathological 
consequences, and despite the above-described unique property of 
tryptase acting as a tetramer, larger amounts of locally administered 
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tryptase β could theoretically lead to adverse events. (3) Finally, 
because active tryptase in working concentrations is rapidly 
degraded and loses its activity, methods and mechanisms of stor-
ing and applying the enzyme in the field need to be developed.
aUThOr cOnTriBUTiOns
All authors have contributed to the collection, analysis, or inter-
pretation of data and have contributed to drafting of the manu-
script. EA and MaMe have written the manuscript, figures were 
made by EA and KS, study conception by MaMe, study design by 
EA, MaMa, and MaMe.
acKnOWleDgMenTs
We thank Saulius Jarmalavicius for discussions and help in 
mass spectrometry, Sina Heydrich and Evelyn Hagen for 
excellent technical assistance, and members of our laboratory 
for discussions.
FUnDing
This study was supported by grants from the German Research 
Foundation (DFG, ME 2668/3-2, ME 2668/2-1 and SO 249/1-1), 
the Else Kröner-Fresenius-Foundation (to MaMe), and the Max 
Planck Society (to KS and DK). We acknowledge support from 
the German Research Foundation (DFG) and the Open Access 
Publication Fund of Charité – Universitätsmedizin Berlin.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
https://www.frontiersin.org/articles/10.3389/fimmu.2018.01532/
full#supplementary-material.
FigUre 7 | Active recombinant human tryptase β detoxifies snake venoms. Venoms were incubated with 10 µg/ml active human recombinant tryptase β and then 
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(Mantel-Cox) test compares treatments to vehicle. ***p < 0.001.
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